Cost Differences Between Oral Anticoagulation Therapies in Patients with Atrial Fibrillation in Finland.

ABSTRACT:

Background

The cost burden of new-onset atrial fibrillation (AF) has not previously been studied with unselected nationwide data.

Objective

We analyzed differences in the distribution and time course of costs from all categories of healthcare services in patients receiving direct oral anticoagulants (DOACs), warfarin, or no anticoagulation during the first year following diagnosis of AF.

Methods

This sub-study of the Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) project comprised all new-onset AF patients from 2011 to 2017 in Finland with an indication for oral anticoagulation treatment. The registry data included information on primary and secondary care services as well as social care services, drug purchases, laboratory data, and reimbursed private care

SUBMITTER: Lehtonen O 

PROVIDER: S-EPMC12634970 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature